Since aberrant PI3K/Akt/mTOR pathway activation plays a crucial role in the pathogenesis of T-ALL, the aim of this research has been to test and compare the therapeutic potential of selective inhibitors, such as GDC-0941, MK-2206, NVP-BAG956, RAD-001, and KU-63794. Here, AKT1 is linked to acute lymphoblastic leukemia.